+38 (095) 926-25-85
Trichocosmetics

Injection options in the therapy of hair pathology

co-authored with Iryna Litus 

Ovcharenko Yu.S., Litus I.A., Isaieva Ya.A. Injection options in the therapy of hair pathology. //Les Nouvelles Esthetiques Украина". – 2017. − No. 6(106). − pp. 72-76. (original in Russian)


Injection methods are gaining popularity in trichology today as part of the comprehensive treatment of various forms of hair loss. While intralesional corticosteroid injections are the first-line therapy for mild alopecia areata and some lymphocytic scarring alopecias, promising injectable compositions have recently been proposed for the treatment of telogen effluvium, androgenetic alopecia, involutional hair loss and seborrhoeic dermatitis, which may be used either as an adjuvant method or as a targeted aetiopathogenetic treatment. 

The classic techniques of superficial and deep nappage, point injections or micropapules, as well as the depot technique traditionally used in trichology, are now complemented by microneedling, fractional mesotherapy and pharmacopuncture.

Given its presumed effect on the release of platelet growth factors, the activation of stem cells and the overexpression of genes associated with hair growth, micropuncture treatment with a scalp roller has been proposed as a new treatment for androgenetic alopecia (AGA). A scalp roller is a drum carrying about 200 microneedles 0.5-2.0 mm long on its surface (in trichology, mesorollers with needles 0.5-1.0 mm long are used). As the roller passes over the skin, it perforates it, creating numerous microchannels through which the applied products penetrate the deep layers of the skin. The microtraumas trigger a local inflammatory reaction accompanied by the synthesis and secretion of many biologically active compounds that stimulate repair processes and the production of collagen and elastin. Micropuncture treatment produces marked vasodilation, which helps to normalise the trophism of the scalp. A randomised study of 100 men with mild to moderate AGA showed that a scalp roller combined with 5% minoxidil lotion was significantly more effective in activating hair growth than minoxidil alone. Despite such promising results, the use of microneedling as a treatment for AGA still needs to be confirmed in clinical studies.

Fractional mesotherapy is a modern method of performing procedures with multiple  microinjections. Precisely set spacing between the needles makes it possible to act on evenly spaced microzones (the fractional principle). As a result, stem cell differentiation is activated in the microtrauma zone from the surrounding tissues, fibroblast proliferation increases and growth factors are released. When the areas of hair loss are treated, hair growth is strongly stimulated through increased vascularisation, enhanced metabolism and cell division in the dermal papillae, and proliferation of the matrix keratinocytes of the hair follicles. A significant increase in the absorption of stimulating products can be regarded as an advantage of fractional mesotherapy. 

Applying therapeutic serums before the microinjections and  immediately after them leads to transdermal absorption of the ingredients that is just  as active as with mesotherapeutic administration. But unlike classic mesotherapy, in fractional mesotherapy the injection depth and the distance between the punctures are strictly set and constant, and both the depth and the speed of the injections can be adjusted. It can be used for plasma therapy, including in the post-operative period in the donor area after hair transplantation. 

Pharmacopuncture (or drug reflexotherapy) combines the principles of homeopathy, acupuncture and drug therapy. It consists of injecting medicinal substances into acupuncture points. In this way, the effect of stimulating biologically active zones is enhanced synergistically by medicines aimed at aetiopathogenetic correction. 

The use of biogenic stimulators and biological products based on placenta hydrolysate by pharmacopuncture is recommended in the treatment of hair disorders.

Hair follicles sit at the intersection of complex neuroendocrine and immune regulation, through which numerous endogenous and exogenous factors, the genome and the epigenome exert both local and systemic effects on the body. What we know is probably only a small fraction of what future discoveries will bring. Greater awareness of the various signalling pathways involved in hair growth may lead to the discovery of new drug targets. Studies by Botchkarev et al. demonstrated that the transition from telogen to anagen is associated with the activation of the Shh, Wnt/beta-catenin/ Lef-1 and Stat3 signalling pathways. In anagen, a huge number of signalling pathways and growth factors (BMP, FGF, HGF, IGF, PDGF, SCF, Shh, Wnt) are active in the epithelium and mesenchyme, and their coordinated activity is necessary for hair formation. It is worth noting that the same factors can have completely opposite effects on the cells of the follicle in different phases of the cycle. Modern research has opened up enormous potential for developing ways to correct and control the hair growth cycle with biologically active substances, growth factors and hormones, and has in fact revolutionised this field.

Promising injectable ingredients and therapeutic compositions for treating hair disorders include recombinant and autologous growth factors, biogenic stimulators,  intralesional corticosteroids, amino acids, hyaluronic acid and sodium succinate, as well as hair follicle cells of autologous origin.

Growth factors

Growth factors — the link between the body's gene expression and the environment — play an important role in regulating the life of the hair follicle. It has now been established that factors such as EGF, TGF-β, IGF-1, HGF, KGF and VEGF are involved in regulating the hair growth cycle.

It is important to note that the fine mechanisms of action of growth factors have not been fully studied. Nevertheless, their use, topically or subcutaneously, to stimulate hair growth is a promising therapeutic method.

In particular, platelet-derived growth factor AA (PDGF-AA) improves the inductive activity of dermal papilla cells in combination with fibroblast growth factor 2 (FGF-2). Insulin-like growth factor 1 (IGF-1) stimulates the proliferation of cycling Ki67+ keratinocytes, while transforming growth factor 1 (TGF-1) protects the proliferative potential of basal keratinocytes by inhibiting cell growth and terminal differentiation. Vascular endothelial growth factor (VEGF) promotes angiogenesis, and PDGF-BB is a powerful chemotactic factor for macrophages and fibroblasts migrating into the wound area. PDGF-BB stimulates these cells to release endogenous growth factors, including TGF-1, which promotes neocollagenesis. 

Preliminary animal studies have shown positive results. A phase I double-blind clinical trial has been completed to assess the safety and efficacy in stimulating hair growth of a bioengineered non-recombinant composition based on human cells containing follistatin, keratinocyte growth factor (KGF) and vascular endothelial growth factor (VEGF).  The study involved 26 people with AGA, and none of them had any side effects after a single intradermal injection. A year later, a statistically significant increase in hair count after the single injection was still present. Another promising product is a combination of FGF-β, VEGF and IGF-1 called “systemic growth factor”. A study was carried out in 112 patients aged 19 to 60 years, who received systemic growth factor by microinjections for 6 months at 2-4-week intervals. Hair count increased by 9.85% and hair thickness by 9.11%.

Growth factors and modulators can act by: interrupting telogen (stem cell activation); stimulating hair growth (stimulating matrix cell proliferation); slowing degeneration (inhibiting apoptosis); improving vascularisation; preserving the specific activity of dermal papilla cells using cell technologies. New products are currently being developed among recombinant or autologous paracrine growth stimulators that are normally produced in dermal papilla cells. It can be assumed that this part of the hair follicle is the main therapeutic target. Great therapeutic potential is offered by autologous platelet-rich plasma as a method that indirectly stimulates the dermal papilla cells. The dermal papilla and the connective tissue sheath are formed from the same progenitor cells as the fibroblasts of the interfollicular dermis, but their gene expression profile and biological functions are radically different. While interfollicular fibroblasts support the growth and differentiation of the overlying epithelial cells (keratinocytes), the dermal papilla and the connective tissue sheath play the main role in regulating hair growth.

Platelet-rich plasma (PRP), isolated from whole blood, is characterised by the presence of  growth factors and stimulating mediators. PRP is an autologous preparation of platelets in concentrated plasma, with a platelet concentration above the physiological level. Activated platelet alpha granules produce numerous growth factors, for example follistatin, keratinocyte growth factor (KGF) and vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and insulin-like growth factor (IGF). These growth factors apparently stimulate cell proliferation and differentiation. Platelet-rich plasma has been found to have a beneficial effect in  bone grafting performed in maxillofacial, orthopaedic and cardiac surgery. Interest in the use of PRP in dermatology has recently grown, for example in tissue regeneration, wound healing, fat grafting and for skin rejuvenation. Recently, PRP has also been proposed as a new treatment for AGA.

The possible effect of PRP on hair growth has been studied in vitro and in vivo in mice. The actual mechanisms of its action on the hair follicle remain debated: in vitro, PRP activates the proliferation of dermal papilla cells and prevents apoptosis, provoking an increase in the expression of Akt and Bcl-2. In addition, PRP takes part in the formation of the hair epithelium and in the differentiation of stem cells into hair follicle cells. Increased expression of FGR-7 leads to a prolonged anagen phase in the hair growth cycle. 

In 2006, Uebel et al. reported new experience of using PRP in the treatment of male pattern AGA. The authors of this study demonstrated that treating follicular units with platelet-rich plasma before transplantation increased hair growth and density. Following this study, several studies were carried out to explore the use of PRP for treating AGA. 

In 2009, Greco et al. published the results of a pilot study of the effect of injecting PRP directly into the scalp skin. Ten people took part in the study, and the results were assessed 4 and 8 months after treatment. In the group of patients who received PRP, the mean hair shaft diameter increased by 9.7% at 4 months and by 6.1% at 8 months. In the control group, which did not receive PRP therapy, the mean hair shaft diameter decreased by 2.8% at 4 months and by 3.5% at 8 months.

In 2010, E. Betsi et al. conducted a pilot study of the clinical efficacy of PRP injections in the treatment of alopecia. The study included 42 patients — 8 women diagnosed with telogen effluvium and 34 men diagnosed with AGA. Results before and after treatment were assessed with the hair pull test and global photographs. After PRP therapy, there was a substantial reduction in hair shedding, a significant increase in hair volume and an improvement in hair quality. The researchers also noted that the improvements were more obvious in patients with a history of up to two years; results were poorer in men with Hamilton-Norwood stage 6-7 baldness.

In 2016, Ramon Grimalt et al. reported the results of a randomised, placebo-controlled, double-blind study in 25 patients with AGA. Each patient's scalp was divided into two parts: one received platelet-rich plasma injections, the other placebo. Each patient underwent a total of three PRP treatments at 1-month intervals. Six months after the first treatment, there was a significant change from baseline in the mean number of anagen hairs, telogen hairs, hair density and terminal hair density. Platelet-rich plasma was also found to increase hair density compared with the control side. For the first time, the authors found a relationship between the number of anagen hairs and patient age > 40 years, AGA onset at ≥25 years, hair density and male sex, age ≤40 years, a positive family history of AGA and disease duration > 10 years. The authors concluded that PRP had a positive effect on AGA and could be considered an adjuvant therapy for this condition.

However, the published results of only a small number of clinical trials of PRP for hair growth cannot be considered objective. Moreover, there is no published consensus protocol for the standard use of PRP, and the use of growth factors and stimulators of their gene expression still needs to be compared with products approved for treating hair. Despite the lack of proven efficacy and of official indications for PRP, the method is gaining popularity with both trichologists and patients. Summing up the views of various authors, a positive effect is noted in telogen effluvium and early-stage AGA, given the experience, however limited, of treating these conditions with PRP. Based on our experience with this technique, the best candidates for PRP are men with AGA up to Hamilton-Norwood stage 4 and women with stage 1-2 female pattern hair loss on the Ludwig scale. A more pronounced effect requires several PRP sessions 6 months apart; each session may include 3 to 6 procedures at 1-month intervals. PRP has a positive effect on AGA and can be used together with approved treatments for this condition, with which it acts synergistically.  The use of this method in other forms of hair loss is experimental, has an insufficient research base and cannot yet be recommended to doctors at large as a treatment. Most likely, the method will be refined in the future to achieve the best treatment results and minimise possible side effects, and a protocol for the standard use of PRP will be clarified and agreed.

Regulatory peptides

Drawing on more than 30 years of experience with peptide bioregulators in medicine, modern approaches to treating hair disorders can be successfully complemented by products based on physiological regulatory peptides. 

Involution of the immune, endocrine and nervous regulatory systems is known to be the main manifestation of ageing. Age-related changes in these systems follow the general laws of ageing of the body but have their own features, determined by the structural and functional specifics of their organs. At the cellular level, this process shows itself as disrupted synthesis and secretion of many signalling molecules, above all peptides. With ageing, the synthesis of many regulatory peptides drops sharply, and target cells lose their sensitivity to them.

Endogenous peptides are involved in regulating cell differentiation and proliferation, changing the functional activity of the genome and protein synthesis depending on the state of the multicellular system.

Peptide regulators are multifunctional. They can act both on differentiated cells of the adult body, triggering cell proliferation while maintaining tissue specificity, and on pluripotent embryonic cells, inducing tissue-specific differentiation. The activity of peptide products is tissue-specific, but the form it takes — cell proliferation or differentiation — depends on the functional state of the biosystem being acted upon.

Today, the set of regulatory peptides is regarded as a self-regulating system that maintains the body's homeostasis through its ability to induce or inhibit the synthesis of other peptides. According to a number of authors, exogenous administration of regulatory peptides or their endogenous release leads to the release of other peptides, for which the original peptide serves as an inducer. These, in turn, induce the release of the next group of peptides, and so on. Biological regulation is thus based on the principle of a regulatory peptide cascade. Consequently, the effects of peptides may appear some time after administration and last for quite a long time. With age, the synthesis and secretion of regulatory peptides decline, and target cells become less sensitive to them. Impaired peptide regulation reduces the resistance of the body's cells and tissues to destabilising factors of both the external and the internal environment. For this reason, an imbalance of peptide regulation may be one of the mechanisms of age-related involution of organs and tissues, accelerated ageing and the development of a number of diseases. As is known, most experts regard AGA as organ-specific accelerated ageing with increased sensitivity of hair follicle fibroblasts to oxidative stress, which makes products based on regulatory peptides relevant both in pattern hair loss and in signs of involutional alopecia.

A vast number of regulatory peptides are known today. Detailed information is available on more than 300 biologically active peptides and their analogues. This suggests that regulatory peptides play a key role in maintaining homeostasis and that it is they, above all, that determine the main parameters of the body's responses to various influences. With their pronounced geroprotective effect, peptide bioregulators are indicated for diseases caused by accelerated ageing. 

Cell renewal involves three components: differentiation (chemokine CXCP 2), proliferation (transcription factor No. 67) and apoptosis (transcription factor p53). It is known that with age the balance between these three characteristics of cell functional activity shifts towards reduced proliferation and differentiation and increased apoptosis, which is seen in almost all tissues of the body. Short peptides act by regulating gene expression and protein synthesis. These peptides stimulate cell proliferation and differentiation and suppress apoptosis, which leads to the restoration of the functions of various organs.

The effect of a mesoinjection product (Meso-Warton P199™) was studied on cultures of dermal fibroblasts modelling the state of cells in (mature) ageing skin. When P18 fibroblasts are cultured with the product, spheroids form within a time comparable to spheroid formation by young P4 fibroblasts. The presence of the product in the growth medium stimulates the “rejuvenation” of the cells and the subsequent restoration of the mesenchymal-epithelial plasticity of the cultured fibroblasts, owing to their restored ability to synthesise extracellular matrix components (fibronectin and collagens) in amounts sufficient to establish cell-to-cell contacts, which affects their ability to form spheroids. Culturing the resulting spheroids with the product stimulates the expression of elastin, type IV collagen, fibronectin and extracellular matrix protein, and the surface cells actively express cytokeratin 19.

Amino acids

Normal supply, intake and transport of proteins, energy, trace elements and vitamins are of fundamental importance for tissues with such high biosynthetic activity as the hair follicle. Since the hair shaft consists almost entirely of protein, dietary protein is critical for producing normal, healthy hair. The mitotic rate is sensitive to the energy value of the diet, provided mainly by carbohydrates stored as glycogen in the outer root sheath of the follicle. Finally, an adequate supply of vitamins and trace elements is needed for the biosynthesis and energy metabolism of the follicle. Protein deficiency and a low-energy diet lead to a shortage of essential amino acids, trace elements and vitamins, which can disturb hair growth and pigmentation. The effect of nutrition on hair growth has been assessed through observations of congenital metabolic disorders and nutrient deficiencies and in studies of dietary supplements in animals and humans. Considerable positive experience has been accumulated worldwide in studying and therapeutically using products containing amino acids (AAs). Amino acid mixtures are increasingly used as highly effective, low-toxicity products for correcting hypoproteinaemia of various origins and for stimulating compensatory and adaptive processes that require activation of protein anabolism. The pharmacological effects of amino acid products result from the activation of metabolic processes in the body, reduced breakdown of the body's own proteins and replenishment of the pool of necessary intermediates. Sulphur-containing amino acids can act as a kind of building material for the structural components of hair and provide energy support for the synthesis of specific cytokeratins. In our opinion, amino acid mesotherapy cocktails for the hair can be recommended in the comprehensive treatment of acute and chronic telogen effluvium, especially when it is caused by deficiencies. 

Synergy of hyaluronic acid and sodium succinate

Clinical and research progress has helped to clarify some of the pathogenic steps leading to androgenetic hair loss. Besides androgens and genetic imbalance, additional pathogenic factors are thought to be involved: the microbial flora, endogenous and exogenous stresses, microinflammation and possibly others. And although other potential factors will obviously be identified, when considering the biological conditions that favour androgenetic alopecia, one must also take into account the individual diversity of triggering agents, as well as the sequence of events or the combination of factors. So far, the influence of oxidative stress, the inflammatory component and developing fibrosis has not been considered in treatment protocols for androgenetic alopecia. A careful analysis of the molecular controls of the immune-mediated physiological degeneration of the hair follicle through apoptosis-mediated organ death will help to understand how to stop the progression of some forms of permanent baldness, which current treatments can only partly halt. This also applies to further research into androgenetic alopecia with inflammatory processes and fibrosis.

The limited possibilities of hair transplantation and the modest efficacy of finasteride and minoxidil in treating androgenetic alopecia point to the need to consider other pathogenic pathways as well. According to histological studies of scalp biopsies, miniaturisation of terminal hairs is often accompanied by perifollicular lymphocytic infiltration and ultimately by fibrosis. It can therefore be assumed that the role of this microscopic follicular inflammation, which causes fibrosis beneath the shortened balding follicle, has not been properly assessed, although it quite probably hinders the renewal of the terminal hair follicle (HF).

Anti-inflammatory agents, antioxidants and antifibrotic agents are not part of the standard treatment of androgenetic alopecia. However, the question arises whether their additional use might improve patients' response to therapy.

Thus, conventional therapy in synergy with indirect action on the trigger factors of AGA is aetiopathogenetically justified. In our opinion, a promising approach in this area is the use of Predermal, which contains 0.55% hyaluronic acid and 1.6% sodium succinate. The discovery of the many-sided biological role of succinic and hyaluronic acids has increased interest in studying these promising compounds. Succinic acid and its salts (succinates) are intracellular metabolites. By acting on the Krebs cycle, succinic acid reduces the formation of pyruvate and lactate, which appear under oxygen deficiency (hypoxia), switching energy metabolism to a more economical pathway. According to studies, succinic acid normalises the levels of the inflammatory mediators histamine and serotonin and improves microcirculation in organs and tissues without changing systemic haemodynamics. Exogenous succinate has been found to have a moderate antihypoxic effect, improving the uptake of circulating oxygen and increasing cell resistance to hypoxia. In the catabolism of succinic acid, other organic acids are utilised, which helps to restore the acid-base balance and prevents inflammatory acidosis, for example after excessive sun exposure. The normalising effect of succinate on cellular energy metabolism has been shown in experimental studies in ageing animals. The high-molecular-weight hyaluronic acid in Predermal promotes hydration and suppresses uncontrolled angiogenesis and the production of the cytokine IL-1b and prostaglandin E2; it has immunosuppressive and detoxifying effects  and improves drainage. The unique combination of active ingredients is complementary: adding sodium succinate enhances the ability of hyaluronic acid to stimulate metabolic processes. Such a combined product is recommended for correcting scar-altered tissue, including striae, as well as signs of photoageing and chronological ageing of the skin. The efficacy of these components in geroprotection has been confirmed clinically and has a solid scientific basis. Thus, the synergy of the pronounced antioxidant action of hyaluronic acid and sodium succinate alters the intracellular redox processes in cells, thereby reducing the susceptibility of the cells' receptor apparatus to negative environmental influences. Studies have shown that succinic acid suppresses inflammation by normalising the levels of the inflammatory mediators histamine and serotonin and stimulates extracellular matrix proteins. The metabolic action of succinic acid is linked to the stimulation of protein synthesis and faster regeneration of damaged cells [25], which is of dominant importance in restoring the HF. An important property of succinic acid is its capillary-protective action, improving blood microcirculation. 

Given the pharmacological properties, the metabolic activity and the substantial evidence base for Predermal, we included it in the comprehensive therapy of patients with AGA.

Materials and methods. The aim of our work was to study the efficacy and tolerability of Predermal in the comprehensive treatment of AGA in women. At the Trichology Institute clinic, we observed 20 women aged 20 to 55 years diagnosed with Ludwig stage I-III AGA. 

Exclusion criteria were acute organic diseases at the time of observation, sensitivity to the components of the product, and previous use of medicines with a potential hair-growth-activating effect. Before and after treatment, all patients underwent the following examinations: a dermatological examination and history of the main disease; trichoscopy with a special ARAMO camera (Republic of Korea) with a x60 lens; a phototrichogram with the specialised diagnostic software TrichoSciencePro©; and digital photo documentation (Nikon D70). 

The patients had patterned hair thinning; microscopy of the hair roots showed their characteristic miniaturisation; unlike the occipital area, the androgen-dependent areas showed anisotrichosis and yellow dots, and the proportion of thinned hairs was increased (on average more than 20%); there was also an increased proportion of telogen hairs (on average up to 33%); the hair pull test was weakly positive and was found in the frontoparietal area of the scalp in 11 of the 20 patients, unlike the occipital area.

To assess the efficacy of adding Predermal to the comprehensive therapy of AGA, all patients were randomised by age, disease duration and severity into two comparable groups. Group I included 10 patients who received 2% topical minoxidil, 1 ml twice a day. Factors that could affect treatment efficacy and the possible development of relapses were taken into account: the clinical features of AGA and the patients' age. The factors needed to choose the right treatment tactics were  assessed, and the presence of concomitant diseases and the possibility of complications after treatment were established. Group II (10 people) was prescribed 2% topical minoxidil, 1 ml twice a day, and Predermal, consisting of 0.55% hyaluronic acid and 1.6% sodium succinate, was added to their comprehensive therapy. Predermal was administered once every 14 days for 12 weeks. A session of 6 procedures. The medium-depth nappage technique was used. Injections were made along imaginary lines dividing the treatment area into 1 cm x 1 cm squares, extending a further 1.5 cm beyond the perimeter of this area.

Study results

The follow-up examination was carried out 12 weeks after the start of treatment. This 12-week study showed that the group treated with Predermal plus minoxidil was statistically superior to the minoxidil group in stimulating hair growth in women with AGA on all main criteria. 

In the subjective assessment, the greatest satisfaction with treatment was reported by patients in group II. Subjectively, after the combined treatment with minoxidil and Predermal, 8 people noted reduced shedding, 10 an improved appearance and 7 faster growth; in addition, 6 people noticed a general improvement in the skin (less tenderness and oiliness of the scalp). All patients in group II reported good tolerability and an almost complete absence of side effects. Comparative macrophotographs show acceptable cosmetic results of treatment with the product. The hair pull test was negative in 100% of group II patients. No case of skin irritation was recorded. Our observations showed the efficacy and safety of Predermal in the comprehensive correction of AGA in women. To improve and maintain the result, it is recommended to continue the comprehensive therapy for up to 6 months in a maintenance regimen of 1 injection procedure once a month.  The proposed comprehensive approach to treating AGA in women, which combines conventional therapy with a hyaluronic acid and sodium succinate product, has shown its efficacy and safety.


Diagnosis and treatment at the Institute

Get a consultation

Dutasteride in mesotherapy

A recent study in 126 female patients investigated the efficacy of local dutasteride injections in the treatment of female pattern baldness (6). A combination of 0.5 mg dutasteride, 20 mg biotin, 200 mg pyridoxine and 2 ml of a 500 mg D-panthenol solution was injected subcutaneously into the crown area by mesotherapy. The injections were repeated weekly for 8 weeks, then every 2 weeks for 4 weeks, and the last session was held at week 16. It was found that 18 weeks after the start of treatment (compared with a control group receiving saline), this method had a positive effect on hair growth in women with female pattern baldness. At week 18, 62.8% of patients showed photographically documented improvement, an increase in hair diameter and reduced hair shedding.

Prostaglandin analogues

Prostaglandin analogues (PGAs), such as latanoprost and bimatoprost, are topical medicines for treating glaucoma and intraocular hypertension. It was later found that these substances promote eyelash growth and pigmentation. Their mechanism of action in hair regrowth is thought to be stimulation of the dermal papilla, leading to the activation of the transition of telogen hairs into the anagen phase (7). To date, there are no data on the use of PGAs for treating female AGA. Treatment of a 59-year-old woman with female pattern baldness with scalp injections of 0.03% bimatoprost once a week for 12 weeks and then once every two weeks for 4 weeks proved ineffective (8).

Intralesional corticosteroids 

For adult patients with mild alopecia areata, intralesional corticosteroids (preferably triamcinolone acetonide) are considered first-line therapy. Every 4–6 weeks, triamcinolone acetonide is given as multiple intradermal injections of 0.1 ml each, 0.5–1 cm apart, with a 30-gauge needle 0.5 inch long. The drug can be used at concentrations from 2.5 to 10 mg/ml, but we recommend 5 mg/ml and 2.5 mg/ml for the scalp and the face respectively. The maximum dose of triamcinolone acetonide per session should be 20 mg. To reduce the pain of the injections, an additional topical anaesthetic cream may be applied before the procedure. This is especially relevant when treating children. If there is no improvement 6 months after the start of treatment, intralesional corticosteroids should be stopped. Side effects include transient atrophy and telangiectasia, which can be avoided by reducing the volume of the drug and the number of injections per site and by avoiding shallow (intraepidermal) injections.

Biological products based on placenta hydrolysate

Clinical experience with organotherapy goes back thousands of years. Many generations of scientists sought to create medicines from the organs, tissues and secretions of animals or humans, assuming that they contain endogenous biologically active substances that help to protect the body from disease and old age. In every era, scientists tried to unravel and explain the cause of the healing action of preparations obtained from allogeneic and xenogeneic organs and tissues. The works of Théophile de Bordeu (1722–1776), Claude Bernard (1813–1878), Addison (1793–1860) and Brown-Séquard (1817–1894) are well known. The French physiologist Brown-Séquard is generally considered the founder of scientific organotherapy: at the age of 72, he tested the stimulating effect of certain organ preparations on himself. He proposed using preparations based on an emulsion of the testes of dogs and guinea pigs as a “remedy against old age”. The team of the Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine in Kharkiv, led by Academician V.I. Hryshchenko, can rightly be considered the pioneer of cell therapy with biologically active preparations of embryonic, foetal and placental origin in the post-Soviet space. Today this field has been reborn and is gaining more and more popularity in various branches of medicine. 

As mentioned above, in recent years biorepair products containing cell growth factors have been actively developed to correct age-related changes: compounds of peptide nature with a molecular weight of about 100 kDa that induce DNA synthesis, regulate cell proliferation and functional activity, and modulate cell motility. Increasing the intensity of regenerative processes is one of the main tasks in solving the problems of hair follicle involution. The discovery of the role of growth factors in hair regeneration aroused active interest in using human and animal placenta preparations to treat pattern hair loss, involutional alopecia and premature greying.

The placenta is an organ containing more than 100 highly active soluble biological compounds that influence the renewal rate of the epidermis and of skin collagen, including virtually all the growth factors needed for skin regeneration. The healing and rejuvenating properties of the placenta have been known since ancient times; they were, and still are, especially highly valued in Eastern medicine, where the placenta is used far more widely than in conventional Western therapy. Japan is considered today's Mecca of regenerative medicine: it has adopted the Act on the Safety of Regenerative Medicine, and bioactive preparations have historically been used there on a mass scale. Placental products showed a high therapeutic effect in treating radiation sickness in survivors of the tragedy of Hiroshima and Nagasaki. Nevertheless, there are questions about the use of the placenta, chiefly concerning the legal side of producing and using such preparations and their safety (microbial and viral contamination, allergenicity, etc.). The use of human cells and tissues in perfume and cosmetic products is banned in Europe; however, the legislative framework in this field is currently still being formed.

Criterion Group I (n=10) Group II (n=10)
Before treatment After treatment Before treatment After treatment
Hair density, number per 1 cm2 261±3.4 275±2.5 262±2.5 280±2.4
Mean hair diameter, µm 57±1.3 60±1.4 56±1.2 61±1.1
Vellus-like hairs, % 21±0.9 18±0.8 20±0.5 14±0.5
Telogen hairs, % 33±0.9 17±0.7 32±0.6 15±0.5

Table 1. Changes in the main morphometric hair parameters in group I and group II patients before and after treatment

The promise of using the regenerative properties of the placenta in cosmetology, trichology and gerontology is obvious. But until recently its use remained problematic because of unsolved tasks such as developing an extraction method that preserves the active properties of the growth factors and a method for targeted delivery of the resulting placenta extract into the skin. However, a new technology for the industrial processing of the placenta, which includes enzymatic extraction and molecular fractionation, provides for fine purification of the biological material and filtration of high-molecular-weight proteins and hormones. Specific labelling makes it possible to isolate growth factors, cytokines and the whole range of biologically active substances, keep them active and concentrate them. 

The active ingredients of the human placenta and the mechanisms of its action on skin and hair are due to the presence of: 11 cell growth factors, including epidermal growth factor EGF, fibroblast growth factor FGF, colony-stimulating factor CSF, insulin-like growth factor 1 IGF 1, nerve growth factor NGF, transforming growth factor beta TGF β and others; a complex of interleukins (IL1 — IL6, IL8, IL10, IL12); 18 amino acids in the L configuration; about a hundred enzymes, including antioxidant defence enzymes; vitamins B1, B2, B6, B12, C, D, E; more than 40 minerals (zinc, sulphur, cobalt, phosphorus, etc.). The complex natural composition of the placental mesotherapy product gives it a comprehensive effect on all pathogenetic links of skin and hair ageing and allows it not only to initiate cell proliferation but also to support cell functional activity through a broad range of biologically active compounds. 

Mesotherapy products of placenta hydrolysate are an innovation in placental therapy for skin and hair. Worldwide, a geroprotector with clinically proven efficacy, which is a human placenta hydrolysate, has been used for more than 50 years to slow the ageing of the human body. The product is intended for intravenous drip administration and has hepatoprotective, detoxifying, immunomodulating and general revitalising effects. It should be stressed that this is precisely a placenta hydrolysate, which contains neither placental cells as such nor placental tissue itself; the hydrolysate is the cell contents: amino acids, peptides, vitamins, etc. Safety is ensured by multistage processing and purification of the placenta and strict step-by-step control. 

It was noticed that after a course of treatment patients reported not only feeling better, greater tolerance of physical exertion and a more balanced mood, but also clear positive changes in the condition of their skin and hair. This became the basis for creating, on the basis of a patented human placenta hydrolysate, new products for injectable mesotherapy to correct and prevent involutional changes in skin and hair. The molecular weight of the placenta hydrolysate components was brought down to 100,000–200,000 Da. Such a low molecular weight of the active components ensures optimal pharmacokinetics of the product when it is injected intradermally. All this determines the high bioavailability of the product's components, their compatibility with human tissues and their clinical efficacy, while the mesotherapy method delivers the product directly to the problem area, creating the maximum concentration of the substance where it is needed.

Data published in the world literature show that the use of placenta hydrolysate is associated with: stimulation of cell proliferation and activation of their synthetic activity; maintenance of an optimal balance among the members of the fibroblast differon, regulation of neocollagenogenesis and glycosaminoglycan synthesis; normalisation of keratinisation, restoration of the epidermal barrier; neoangiogenesis and activation of microcirculation in the skin; normalisation of immunocompetent cell function, restoration of local immunity; optimisation of melanogenesis; antioxidant protection; normalisation of tissue respiration; regulation of apoptosis.

In conclusion, it must be stressed that although the placenta has been proving its high therapeutic and rejuvenating properties for centuries, only highly purified, certified products from reputable manufacturers guarantee the safety and high efficacy of anti-age therapy, and such therapy can be recommended in the comprehensive treatment of involutional loss of hair and pigment, chronic or acute telogen effluvium of toxic or psycho-emotional origin, seborrhoeic dermatitis and androgenetic alopecia. The recommended course of treatment is 10 procedures, once a week, at a dose of 2-4 ml per procedure. Placenta hydrolysate products have specific routes of administration: for treating hair loss and scalp diseases they are given intradermally and subcutaneously; however, in our opinion, such biorepair products show the greatest synergy of action when used by pharmacopuncture. 

Therapeutic strategies of the future — using autologous hair follicle cells

As shown earlier, one of the most intriguing features of the dermal papilla and the dermal sheath is that they control hair growth in adult skin. Throughout life, hair follicles go through growth cycles — anagen, catagen and telogen — and it is the signals coming from the dermal papilla and the dermal sheath that are the fundamental condition for passing through all these stages of the cycle. Perhaps even more interesting is the fact that the dermal papilla and the dermal sheath show similar properties ex vivo. When these mesenchymal tissues are isolated from hair follicles (of both rodents and humans) and transplanted onto hairless skin or inactivated follicles, they can stimulate the growth of new hair follicles and fibres in the recipient epithelium. 

In December 2010, based on the results of the preclinical studies described, RepliCel launched the first phase I / IIa clinical trial in humans to develop a cell therapy for pattern hair loss by injecting autologous hair follicle cells. The aim of the study was to create a safe, long-acting treatment for pattern hair loss suitable for both women and men, and to replace fairly invasive hair transplantation with minimally invasive injections. The phase I/IIa  clinical trial (TS001-2009) on the safety of autologous dermal sheath cup cells of the human hair follicle in the treatment of androgenetic alopecia (clinicaltrials.gov: NCT01286649) was successfully completed on 6 May 2011. The study was conducted at the National Research Institute of Dermatology and Venereology in Georgia under the direction of Professor Nino Lordkipanidze. The next stage of this exciting clinical study of dermal sheath cell therapy, examining efficacy, is planned at a university clinic in Japan in early 2016. Shiseido will act as the specialised laboratory.  

Thus, certain types of follicular mesenchymal cells can activate the growth of new hair after transplantation into hairless skin. And although such a procedure can theoretically be regarded as autologous cell therapy, the hair follicle has immune privilege, and dermal sheath cells in homografts are known not to be rejected and to induce hair growth. The immune privilege of the follicle is thought to be explained by the virtual absence of major histocompatibility complex (MHC) class I and II antigens in it, so that dermal papilla and sheath cells have considerably greater advantages than other cell types for use in allogeneic cell products.

Apart from the role that papilla and sheath cells play in the hair follicle growth cycle and in skin development, they also have other little-studied features of interest to regenerative medicine. Dermal sheath cells produce abundant collagen I, which is why RepliCel Life Sciences is currently conducting a phase I / II study of autologous dermal sheath cells isolated from hair follicles for the treatment of chronic Achilles tendinopathy in 28 patients (clinical trial No. NCT02330146). At the time this chapter was written, results on the efficacy of dermal sheath cells in tendon repair had not yet been obtained, but previous studies using skin fibroblasts demonstrated their efficacy.

Both dermal papilla cell populations and dermal sheath cell populations have multipotent properties when isolated from the follicle and grown in cell culture. These hair-follicle-derived cells are known to be able to differentiate in vitro into cells of several other mesenchymal lineages, in particular osteoblasts, adipocytes, contractile smooth muscle cells and chondrocytes. Given the immunogenic properties of dermal papilla and dermal sheath cells combined with their multipotency and accessibility, they are a source of cells that could be used in areas such as cardiac tissue regeneration or bone and cartilage replacement in joint repair.

Summary

Growth factors and biologically active substances are used more and more actively in trichology practice. However, despite almost ready technological solutions and a good fundamental rationale, these approaches require careful study of the delayed consequences of long-term use of substances that act very intensely on all the main parameters of cellular homeostasis: growth, migration, apoptosis and differentiation. It is worth making sure that such a forceful intervention in the network of intercellular and intracellular processes will not cause adverse events. Nevertheless, when used wisely and on sound grounds, these approaches have very good prospects.

Key references

  1. Трихология / А. Злотогорский, Д. Шапиро [и др.]; под ред. А. Литуса; пер. с англ. Ю. Овчаренко. – К.: Рудь, 2016. – 256 с., ил.
  2. Ralph M. Trüeb. Desmond J. Tobin (Eds.) Aging Hair — Springer, 2010. — 270 p. 
  3. Sperling LC, Lupton GP (1995) Histopathology of nonscarring alopecia. J Cutan Pathol:97–114
  4. Jaworsky C, Kligman AM, Murphy GF (1992) Characterisation of inflammatory infiltrates in male pattern alopecia: implication for pathogenesis. Br J Dermatol 127: 239–246
  5. Philpott MP, Sander DA, Bowen J, Kealey T (1996) Effects of interleukins, colony stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata Br J Dermatol 135:942–948
  6. Willimann B, Trьeb RM (2002) Hair pain (trichodynia): frequencyand relationship to hair loss and patient gender. Dermatology 205:374–377
  7. Blumeyer A, Tosti A, Messenger A et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9: S1-S57.
  8. Trueb R.M. et al., The Value of Dietary Supplements: Results of a Double-Blind Placebo-Controlled Study with Oral Combination of Cystine, Yeast and Pantothenic Acid. - 2005
  9. Li L., Mignone J., Yang M., Matic M., Penman S., Enikolopov G., Hoffman R.M. Nestin expression in hair follicle sheath progenitor cells // Proc Natl Acad Sci. – 2003.–USA 100: 9958–9961.
  10. К вопросу об экзогенной регуляции физиологической регенерации кожи человека. В.А. Березовский, О.В. Богомолец, Н.Н.Деркач, И.Г. Литовка, С.П. Весельский, Л.Л. Лукаш, Т.А. Рубан, Р.В. Янко - Украинский журнал дерматологии, венерологии, косметологии, №3- 2011
  11. Stern R (August 2004). «Hyaluronan catabolism: a new metabolic pathway». Eur J Cell Biol 83 (7): 317-25. PMID 15503855
  12. Цепколенко В, Зацерклянный А.  РЕДЕРМАЛИЗАЦИЯ с позиций ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ //Нувель Эстетик 5 (63)/2010, стр. 39.
  13. Коржов В. Сукцинат натрия // cabines ukraine / февраль 2011, стр.60-61.
  14. Lee SH, Zheng Z, Kang JS et al (2015) Therapeutic efficacy of autologous platelet-rich plasma and polydeoxyribonucleotide on female pattern hair loss. Wound Repair Regen 23(1):30-6.
  15. 2. Li ZJ, Choi HI, Choi DK et al (2012) Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg 38: 1040–6.
  16. 3. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):213-9.
  17. Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, Ibrahim M.
  18. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013 Jun;27(6):686-93.
  19. 7. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013 Aug 29;5:541-56.
  20. Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol. 2011;10(7):795–798.
  21. Alexandrescu D.T., Kaufmann C.L., Dasanu C.A. The cutaneous epidermal growth factor network: can it be translated clinically to stimulate hair growth? Dermatol Online J. 2009; 15: 1.
  22. Commo S., Gillard 0., Bernard B.A. The human hair follicle contains two distinct K19 positive compartments in the outer root sheath: A unifying hypothesis for stem cell reservoir? Differentiation. 2000; 66: 157-64.
  23. Cotsarelis G., Sun T.-T., Lavker R.M. Label-retaining cells reside in the bulgier of piloseba- ceous unit: Implications for follicular stem cells, hair cycle and skin carcinogenesis. Cell. 1990; 61: 1329-37.
  24. Danilenko D.M., Ring B.D., Yanagihara D., Benson W., Wiemann B., Starnes C.O., Pierce G.F. Keratinocyte growth factor is an important endogenous mediator of hair follicle growth development and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia. Am J Pathol. 1995; 147: 145-54.
  25. Greco V., Chen T., Rendl M., Schober M., Pasolli H. A two-step mechanism for stem cell activation during hair regeneration. Cell Stem Cell. 2009; 4: 155-69.
  26. Guo L, Degenstein L., Fuchs E. Keratinocyte growth factor is required for hair development but not for wound healing. Genes Develop. 1996; 10: 165-75.
  27. Inui S., Itami S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2011; 61: 1-6.
  28. Kim B.J., Kim S.Y., Kwon T.R., Lee Y.H., Song Y.S. Platelet-rich plasma promoting hair growth in human hair follicle dermal papilla cells associated with VEGF and VEGFR-2. J Invest Dermatol. 2013; 133: 1398.
  29. Lavker R.M., Sun T.-T., Oshima H. et al. Hair follicle stem cells. J Invest Dermatol Symp Proc. 2003; 8: 28-38.
  30. Li M., Marubayashi A., Nakaya Y. et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001; 117: 1594-600.
  31. Li W., Man X.Y., Li C.M., Chen J.Q., Zhou J. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp Cell Res. 2012; 318: 1633-40.
  32. Morris R.J., Potten C.S. Highly persistent label retaining cells in the hair follicles of me and their fate following induction of anagen. J Invest Dermatol. 1999; 112: 470-5.
  33. Nixon A.J., Broad L., Saywell D.P., Pearson A.J. Transforming growth factor alpha immunoreacti- vity during induced hair follicle growth cycles in sheep and ferrets. J Histochem Cytochem. 1996; 4: 377-87.
  34. Philpott M.P., Green M.R., Kealey T. Rat hair follicle growth in vitro. Br J Dermatol. 1992; 127: 600-7.
  35. Ro B.l. Systemic growth factor treatment on the patients with androgenetic alopecia. J Invest Dermatol. 2013; 133: 1400.
  36. Schmidt D., Belser E., Zulli F. The FGF7 and Noggin genes are key targets to treat hair loss. SOFWJ. 2013; 139: 18-22.
  37. Tsuboi R. Growth factors and hair growth. Korean J Invest Dermatol. 1997; 2: 103-8.
  38. Tsuji Y., Denda S., Soma T., Raftery L., Momoi T., Hibino T. A potential suppressor of TGF-beta delays catagen progression in hair follicles. J Invest Dermatol Symp Proc. 2003; 8(1): 65-8.
  39. WangJ.M., Zhang J.T. Progress in relevant growth factors promoting the growth of hair follicle. Am J Anim Vet Sci. 2012; 7: 104-11.
  40. Wilson C., Cotsarelis G., Wei Z.G. et al. Cells within the bulge region of mouse hair follicle transiently proliferate during early anagen: heterogeneity and functional differences of various hair cycles. Differentiation. 1994; 55: 127-36.
  41. Xu Y., Xia W., Baker D., Zhou J., Cha H.C. et al. Receptor-type protein tyrosine phosphatase beta (RPTP-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (HGFR/Met) function. J Biol Chem. 2001; 286: 15980-8.
  42. Zhao J., Harada N., Kurihara H., Nakagata N., Okajim K. Dietary isoflavone increases insulinlike growth factor-1 production, thereby promoting hair growth in mice. J Nutr Biochem. 2011; 22: 227-33.
  43. Zimber M.P., Ziering C., Zeigler F. et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol. 2011; 10(11): 1308-12.
  44. Azzena B., Mazzoleni F., Abatangelo G., Zavan B., Vindigni V. Autologous platelet-rich plasma as an adipocyte in vivo delivery system: case report. Aesthetic Plast Surg. 2008; 32(1): 155-8; discussion 159-61.
  45. Betsi E.-E., Germain E., Kalbermatten D., Tremp M., Emmenegger V. Platelet-rich plasma injection is effective and safe for the treatment of alopecia. EurJ Plast Surg. 2013; 36(7): 407-12.
  46. Cervelli V., Garcovich S., Bielli A., Cervelli G., etal.The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation. Biomed Res Int. 2014; Article ID 760709.
  47. d’Ovidio R., Roberto M. Limited effectiveness of platelet rich plasma treatment on chronic severe alopecia areata. Hair TherTransplant. 2014; 4: 116.
  48. Gkini M.A., Kouskoukis A.E., Tripsianis G., Rigopoulos D., Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan AesthetSurg. 2014; 7:213-9.
  49. Greco J., Brandt R. The effects of autologous platelet rich plasma and various growth factors on non-transplanted miniaturized hair. HairTransplant Forum International, March-April 2009; 49-50.
  50. Kakudo N., Minakata T., Mitsui T. et al. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg. 2008; 122(5): 1352-60.
  51. Khatu S.S., More Y.E., Gokhale N.R., Chavhan D.C., Bendsure N. Platelet-rich plasma in androgenic alopecia: myth or an effective tool. J Cutan Aesthet Surg. 2014; 7(2): 107-10.
  52. Kozlowska U., Blume-Peytavi U., Kodelja V. etal. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res. 1998; 290(12): 661-8.
  53. Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plastic Reconst Surg. 2008; 122(5): 1352-60.
  54. Lachgar S., Moukadiri H., Jonca F., et al., Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells. J Invest Dermatol. 1996; 106(1): 17-23.
  55. Li Z.J., Choi H.-l., Choi D.-K. et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012; 38(7): 1040-6.
  56. Mecklenburg L., Tobin D.J., Muller-Rover S. et al. Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol. 2000; 114(5): 909-16.
  57. Schiavone G., Raskovic D., Greco J., Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. Dermatol Surg. 2014; 40(9): 1010-9.
  58. Takikawa M., Nakamura Sh., Nakamura S. et al. Enhanced effect of platelet-rich plasma containing a new carrier on hair growth. Dermatol Surg. 2011; 37(12): 1721-9.
  59. Trink A., Sorbellini E„ Bezzola P. et al. A randomized, double blind, placebo- and active-controlled, half-head study to evaluate the effect of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013; 169(3): 690-4.
  60. Uebel C.O. et al. The role of platelet plasma growth factors in male pattern baldness surgery. Plastic Reconst Surg. 2006; 118(6): 1458-66.
  61. Рыжак Г. А., Королькова Т. Н., Войтон Е. В. Геронтокосметология: профилактика и коррекция возрастных изменений кожи. СПб.: ООО Коста, 2006.160 с.
  62. Хавинсон В. X. Молекулярные основы пептидергической регуляции старения. СПб.: Нау^ 2011.174 с.
  63. Хавинсон В. X., Кузник Б. И., Рыжак Г.А. Пептидные биорегуляторы — новый класс гер0” протекторов. Сообщение 1. Результаты экспериментальных исследований //Успехи геронтол. 2012. Т. 25, № 4. С. 696-708.
  64. Хавинсон В. X., Кузник Б. И., Рыжак Г.А. Пептидные биорегуляторы — новый класс геропротекторов. Сообщение 2. Результаты клинических исследований // Успехи геронтол. 2013. Т. 26, № 1. С. 20-37.
  65. Elliott, K.; Stephenson, T. J.; Messenger, A. G. Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses. J. Invest. Dermatol. 1999, 113 (6), 873−877.
  66. Messenger, A. G. The culture of dermal papilla cells from human hair follicles. Br. J. Dermatol. 1984, 110 (6), 685−689.
  67. Bassukas, I. D.; Arai, A.; Schell, H.; Hornstein, O. P. Growth and cell kinetics of human hair papilla cells in vitro. An autoradiographic and flow cytometric study. Cell Proliferation 1991, 24 (4), 367−374.
  68. Gamie, Z.; Tran, G. T.; Vyzas, G.; Korres, N.; Heliotis, M.; Mantalaris, A.; Tsiridis, E. Stem cells combined with bone graft substitutes in skeletal tissue engineering. Expert Opin. Biol. Ther. 2012, 12 (6), 713−729.
  69. Ng, M. H.; Duski, S.; Tan, K. K.; Yusof, M. R.; Low, K. C.; Rose, I. M.; Mohamed, Z.; Bin Saim, A.; Idrus, R. B. Repair of segmental load-bearing bone defect by autologous mesenchymal stem cells and plasma-derived fibrin impregnated ceramic block results in early recovery of limb function. BioMed Res. Int. 2014, 2014, 345910.
  70. Agabalyan, N. A.; Borys, B. S.; Sparks, H. D.; Boon, K.; Raharjo, E. W.; Abbasi, S.; Kallos, M. S.; Biernaskie, J. Enhanced Expansion and Sustained Inductive Function of Skin-Derived Precursor Cells in Computer-Controlled Stirred Suspension Bioreactors. Stem Cells Transl. Med. 2017, 6 (2), 434−443.
  71. Murphy, W. L.; McDevitt, T. C.; Engler, A. J. Materials as stem cell regulators. Nat. Mater. 2014, 13 (6), 547−557. 
  72. Celiz, A. D.; Smith, J. G.; Langer, R.; Anderson, D. G.; Winkler, D. A.; Barrett, D. A.; Davies, M. C.; Young, L. E.; Denning, C.;
  73. Alexander, M. R. Materials for stem cell factories of the future. Nat. Mater. 2014, 13 (6), 570−579.
  74.  Carotti D, Allegra E. An approach to chemical characterization of human placental extracts: proteins, peptides, and amino acids analyses. Physiol Chem Phys. 1981;13:129–36.  [PubMed]
  75. Kong M, Park SB. Effect of human placental extract on health status in elderly Koreans. Evid Based Complement Alternat Med. 2012;2012:732915. [PMC free article][PubMed]
  76. Datta P, Bhattacharyya D. Spectroscopic and chromatographic evidences of NADPH in human placental extract used as wound healer. J Pharma Biomed Anal. 2004;34:1091–8. doi: 10.1016/S0731-7085(03)00654-X.[PubMed] [Cross Ref]
  77. Jash A, Kwon HK, Sahoo A, Lee CG, So JS, Kim J, et al. Topical application of porcine placenta extract inhibits the progression of experimental contact hypersensitivity. J Ethnopharmacol. 2011;133:654–62. doi: 10.1016/j.jep.2010.10.054.  [PubMed] [Cross Ref]
  78.  Biswas TK, Auddy B, Bhattacharyya NP, Bhattacharyya S, Mukherjee B. Wound healing activity of human placental extract in rats. Acta Pharmacol Sin. 2001;22:1113–6.[PubMed]
  79. Kang HS, Chung HY, Kim JY, Son BW, Jung HA, Choi JS. Inhibitory phlorotannins from the edible brown alga Ecklonia stolonifera on total reactive oxygen species (ROS) generation. Arch Pharm Res. 2004;27:194–8. doi: 10.1007/BF02980106.  [PubMed] [Cross Ref]
  80. Li Y, Qian ZJ, Ryu B, Lee SH, Kim MM, Kim SK. Chemical components and its antioxidant properties in vitro: an edible marine brown alga. Ecklonia cava Bioorg Med Chem. 2009;17:1963–73. doi: 10.1016/j.bmc.2009.01.031.  [PubMed] [Cross Ref]
  81.  Fukuyama Y, Kodama M, Miura I, Kinzyo Z, Mori H, Nakayama Y, et al. Anti-plasmin inhibitor. VI. Structure of phlorofucofuroeckol A, a novel phlorotannin with both dibenzo-1,4-dioxin and dibenzofuran elements, from Ecklonia kurome Okamura. Chem Pharm Bull. 1990;38:133–5. doi: 10.1248/cpb.38.133.  [PubMed][Cross Ref]
  82. Ahn MJ, Yoon KD, Min SY, Lee JS, Kim JH, Kim TG, et al. Inhibition of HIV-1 reverse transcriptase and protease by phlorotannins from the brown alga Ecklonia cava. Biol Pharm Bull. 2004;27:544–7. doi: 10.1248/bpb.27.544.[PubMed] [Cross Ref]
  83. 16. Han ES, Kim JW, Eom MO, Kang IH, Kang HJ, Choi JS, et al. Inhibitory effects of Ecklonia stolonifera on gene mutation on mouse lymphoma tk+/− locus in L5178Y-3.7.2C cell and bone marrow micronuclei formation in ddY mice. Environ Mutagen Carcinogen. 2000;20:104–11.
  84. Kang SM, Heo SJ, Kim KN, Lee SH, Yang HM, Kim AD, et al. Molecular docking studies of a phlorotannin, dieckol isolated from Ecklonia cava with tyrosinase inhibitory activity. Bioorg Med Chem. 2012;20:311–6. doi: 10.1016/j.bmc.2011.10.078.  [PubMed] [Cross Ref]
  85. 18. Jung HA, Jung HJ, Jeong HY, Kwon HJ, Ali MY, Choi JS. Phlorotannins isolated from the edible brown alga Ecklonia stolonifera exert anti-adipogenic activity on 3 T3-L1 adipocytes by downregulating C/EBPα and PPARγ Fitoterapia. 2014;92:260–9. doi: 10.1016/j.fitote.2013.12.003.  [PubMed] [Cross Ref]
  86. Joe MJ, Kim SN, Choi HY, Shin WS, Park GM, Kang DW, et al. The inhibitory effects of eckol and dieckol from Ecklonia stolonifera on the expression of matrix metalloproteinase-1 in human dermal fibroblasts. Biol Pharm Bull. 2006;29:1735–9. doi: 10.1248/bpb.29.1735.[PubMed] [Cross Ref]
  87. Kang MC, Kim KN, Kang SM, Yang X, Kim EA, Song CB, et al. Protective effect of dieckol isolated from Ecklonia cava against ethanol caused damage in vitro and in zebrafish model. Environ Toxicol Pharmacol. 2013;36:1217–26. doi: 10.1016/j.etap.2013.09.018.[PubMed] [Cross Ref]
  88.  Mayo JC, Tan DX, Sainz RM, Natarajan M, Lopez-Burillo S, Reiter RJ. Protection against oxidative protein damage induced by metal-catalyzed reaction or alkylperoxyl radicals: comparative effects of melatonin and other antioxidants. Biochim Biophys Acta. 2003;1620:139–50. doi: 10.1016/S0304-4165(02)00527-5.  [PubMed][Cross Ref]
  89. Kim YJ, Uyama H, Kobayashi S. Inhibition effects of (+)-catechin-aldehyde polycondensates on proteinases causing proteolytic degradation of extracellular matrix. Biochem Biophys Res Commun. 2004;320:256–61. doi: 10.1016/j.bbrc.2004.05.163.  [PubMed] [Cross Ref]
  90. Jang SK, Yu JM, Kim ST, Kim GH, Park da W, Lee do I, et al. An Aβ42 uptake and degradation via Rg3 requires an activation of caveolin, clathrin and Aβ-degrading enzymes in microglia. Eur J Pharmacol. 2015;758:1–10. doi: 10.1016/j.ejphar.2015.03.071.  [PubMed] [Cross Ref]
  91. Afanas’ev IB. Free radical mechanisms of aging processes under physiological conditions. Biogerontology. 2005;6:283–90. doi: 10.1007/s10522-005-2626-z.  [PubMed][Cross Ref]
  92. 25. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298–300. doi: 10.1093/geronj/11.3.298.  [PubMed] [Cross Ref]
  93. Alexeyev MF. Is there more to aging than mitochondrial DNA and reactive oxygen species? FEBS J. 2009;276:5768–87. doi: 10.1111/j.1742-4658.2009.07269.x. [PMC free article]  [PubMed][Cross Ref]
  94. Lagouge M, Larsson NG. The role of mitochondrial DNA mutations and free radicals in disease and ageing. J Intern Med. 2013;273:529–43. doi: 10.1111/joim.12055.[PMC free article]  [PubMed] [Cross Ref]
  95. Fujita S, Volpi E. Amino acids and muscle loss with aging. J Nutr. 2006;136:277–80. [PMC free article][PubMed]